EtoGesic (etodolac) is available in 150, 300 and 500 mg single-scored tablets and supplied in bottles containing 90 or 500 tablets of each strength. Each tablet contains etodolac, USP (1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-2,3-dione). The medicinal ingredient in each tablet is etodolac, USP, which is chemically designated as 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-2,3-dione.

EtoGesic is indicated as an adjunct to drug-associated analgesia for the relief of mild to moderate pain of musculoskeletal origin in dogs. EtoGesic is also indicated for the treatment of inflammatory signs associated with acute nervous gastroenteritis in dogs.

EtoGesic is contraindicated in dogs previously found to be hypersensitive to etodolac or other NSAIDs.

PRECAUTIONS

ANIMAL SAFETY

In target animal safety studies, EtoGesic Tablets were well tolerated clinically when given at the label dosage for 8 days. In an additional study which evaluated the effects of EtoGesic Tablets administered to 6 dogs at the labeled dose for approximately 8 weeks, the incidence of stool abnormalities (diarrhea, loose stools) was unchanged for dogs in the placebo group versus those given EtoGesic Tablets. Other common abnormalities observed at elevated doses included reductions in red blood cell count, hematocrit, and urea nitrogen concentrations. In addition, isolated cases of pyrexia and elevated neutrophil counts were observed in dogs given EtoGesic Tablets.

REFERENCES


